Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.
Type:
Application
Filed:
April 7, 2023
Publication date:
November 16, 2023
Applicant:
IVERIC bio, Inc.
Inventors:
Samir Patel, Richard Everett, Douglas Brooks, Shane Xinxin Tian
Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-05 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.
Type:
Application
Filed:
April 7, 2023
Publication date:
November 16, 2023
Applicant:
IVERIC bio, Inc.
Inventors:
Samir Patel, Richard Everett, Douglas Brooks, Shane Xinxin Tian
Abstract: A bioreactor including a bioreactor body, wherein the bioreactor body includes a first substrate and an opposing second substrate, a pathway extending through the bioreactor body and being formed by a first channel defined in the first substrate and an opposing second channel defined in the second substrate, a first inlet for introducing a first fluid flow to the first channel, a second inlet for introducing a second fluid flow to the second channel, a first outlet for permitting the first fluid flow to exit the first channel, a second outlet for permitting the second fluid flow to exit the second channel, a membrane disposed in the pathway between the first and second channels and having a plurality of pores sized to selectively capture, in the first channel, a biological source material and to permit biological products to be collected from the bioreactor.
Abstract: The present application is directed to methods and compositions that are useful for reducing the number of myeloid-derived suppressor cells (MDSC), tumor associated macrophages (TAM), or both in a subject. The methods include administering an antigen binding protein that binds to an antigen expressed by MDSC and/or TAM, or administering a modified T cell or NK-92 cell that expresses an antigen binding protein that binds to an antigen expressed by MDSC and/or TAM, or a combination of both, to a subject. For example, the antigen binding protein can bind to CD33 expressed by MDSC and/or TAM. The methods and compositions are useful for treating a disease associated with MDSC and/or TAM infiltration into a tissue or tumor.
Type:
Grant
Filed:
March 11, 2019
Date of Patent:
November 14, 2023
Assignee:
Immunity Bio, Inc.
Inventors:
Patrick Soon-Shiong, Hans G Klingemann, Laurent H Boissel, Himani Chinnapen, Abhijit Dandapat
Abstract: The invention relates in part to a method of maintaining heavy metal homeostasis in healthy humans, comprising chronically administering to healthy humans a pharmaceutical composition consisting of from about 1 mg to less than about 200 mg of Posiphen or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable excipients, on a once a day basis. By virtue of this method, prophylactic treatment of a potential disease state such as a neurodegenerative disease, cardiovascular homeostasis, cancer, vital organ homeostasis, and the like. The invention also relates in part to a method of restoring heavy metal homeostasis in sick patients, comprising chronically administering to a sick patient a pharmaceutical composition consisting of from about 1 mg to less than about 200 mg of Posiphen or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable excipients, on a once a day basis.
Abstract: The present disclosure relates to a bispecific antibody that specifically binds to alpha-synuclein and IGF1R, and an use of the bispecific antibody for the prevention, treatment and / or diagnosis of synucleinopatheis associated with alpha-synuclein or alpha-synuclein aggregates, and can allow the alpha-synuclein antibody or an antigen-binding fragment thereof to penetrate the blood brain barrier to exert its action in the brain, and extend the half-life to maintain the efficacy for a long time.
Type:
Application
Filed:
December 8, 2022
Publication date:
November 9, 2023
Applicant:
ABL BIO INC.
Inventors:
Sungwon AN, Jinhyung AHN, Byungje SUNG, Dongin KIM, Daehae SONG, Jaehyun EOM, Yong-Gyu SON, Juhee KIM, Kyungjin PARK, Jinwon JUNG, Bora LEE, Hyesu YUN
Abstract: A system and process use artificial intelligence to evaluate the toxicity of drugs on cells. In some embodiments, a convolutional neural network is trained to identify features in cells and thereafter identify when structural changes in cells are signs of damage from exposure to a drug. Some embodiments use a 2-class deep neural network, comparing drug-treated cells to controls, to learn which images may show signs of toxicity as a result of the drug. In some applications, the system may capture images from a time-lapse experiment to determine from the cell cultures how a drug affects a cell type over time.
Type:
Grant
Filed:
February 14, 2020
Date of Patent:
November 7, 2023
Assignee:
CURI BIO, INC.
Inventors:
Seyyedeh Mahnaz Maddah, Kevin Edward Loewke
Abstract: The present disclosure relates to methods for producing oxygenated terpenoids, and preparation of compositions and formulations thereof. Polynucleotides, derivative enzymes, and host cells for use in such methods are also provided.
Type:
Grant
Filed:
November 22, 2021
Date of Patent:
November 7, 2023
Assignees:
GIVAUDAN SA, MANUS BIO INC.
Inventors:
Ajikumar Parayil Kumaran, Chin Giaw Lim, Liwei Li, Souvik Ghosh, Christopher Pirie, Anthony Qualley, Geoff Marshall-Hill, Martin Preininger
Abstract: The present invention relates generally to compositions (e.g., gels, suppositories, and the like) and methods for modulating the acidity and/or alkalinity of the fluidic environment of human reproductive organs and systems (e.g., vagina, and cervical fluids/mucus). In particular, the compositions and methods of the present invention are useful for modulating the acidity and/or alkalinity of the fluids within the vagina and that bathe the mucosal surfaces therein. The compositions and methods are useful for promoting and/or sustaining colonization of the vagina by beneficial and/or typically nonpathogenic species of commensal microorganisms (e.g., bacterial species). Additionally, the compositions and methods are useful as adjuvants and/or carriers for introducing one or more species of beneficial commensal microorganisms (e.g., bacterial species) into the vagina such as lactic acid producing bacteria, and in particular, species of Lactobacilli.
Abstract: The invention provides methods and reagents for detecting luciferase in biological samples. The methods and reagents of the present invention allow detecting fungal luciferase or a functional analog thereof.
Abstract: The present disclosure features useful compositions and methods to treat disorders for which deamination of an adenosine in an mRNA produces a therapeutic result.
Type:
Application
Filed:
May 3, 2023
Publication date:
October 26, 2023
Applicant:
Korro Bio, Inc.
Inventors:
Andrew W. Fraley, Steven Robinette, Nessan Bermingham, Mallikarjuna Reddy Putta
Abstract: A system for searching for a pathological image includes: an autoencoder having an encoder for receiving an original pathological image and extracting a feature of the original pathological image, and a decoder for receiving the feature of the original pathological image extracted by the encoder and generating a reconstructed pathological image corresponding to the original pathological image; a diagnostic neural network for receiving the reconstructed pathological image generated by the autoencoder that has received the original pathological image, and outputting a diagnosis result of a predetermined disease; and a training module for training the autoencoder and the diagnostic neural network by inputting a plurality of training pathological images, each labeled with a diagnosis result, into the autoencoder. The autoencoder is trained by reflecting the diagnosis result of the reconstructed pathological image output from the diagnostic neural network.
Type:
Grant
Filed:
October 4, 2019
Date of Patent:
October 24, 2023
Assignee:
DEEP BIO INC.
Inventors:
Tae Yeong Kwak, Sang Hun Lee, Sun Woo Kim
Abstract: This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.
Abstract: The present invention relates to the identification of a group of microorganisms, which are relatively abundant in the microbial communities associated with fruits and vegetables typically consumed raw and therefore transient or permanent members of the human microbiota. The consumption of mixtures of these microbes at relevant doses will produce a beneficial effect in the host by reducing the propensity to diabetes, obesity and metabolic syndrome mediated in part by production of short chain fatty acids to enhance colonic butyrate production. Therapeutic methods of the invention involve the use of live microorganisms or metabolites derived from said microorganisms to establish a microbial composition in the mammalian host that will improve significantly the ability to control weight, reduce the onset of diabetes, obesity and metabolic syndrome, and improve overall health.
Type:
Grant
Filed:
March 20, 2020
Date of Patent:
October 24, 2023
Assignee:
SOLAREA BIO, INC.
Inventors:
Gerardo V. Toledo, Tracy Mincer, Jahir Mauricio Gutierrez Bugarin, Jillian DeWalt, Eric Schott, Maria Juliana Soto Giron
Abstract: The present disclosure relates to antibodies that bind to human CD94, as well as methods, uses, polynucleotides, vectors, host cells, and pharmaceutical compositions related thereto. In some embodiments, the antibodies are human or humanized antibodies that bind to human CD94 and do not block binding between CD94 and HLA-E. In some embodiments, the antibodies cross-react with cynomolgus CD94. In some embodiments, the antibodies do not promote internalization of surface-expressed CD94 to the extent of existing antibodies. In some embodiments, the antibodies promote ADCC targeting cells that express human CD94, e.g., on the cell surface.
Abstract: The disclosure concerns a method of treating complications of acute or chronic hyperglycemia and/or diet-induced obesity comprising: (i) determining whether a patient suffers from complications related to acute or chronic hyperglycemia and/or diet induced obesity, and if so, (ii) administering to the patient in need thereof a selective inhibitor of soluble TNF-? but not transmembrane TNF-?. For purposes herein, complications of acute or chronic hyperglycemia and/or diet-induced obesity include: diabetes mellitus, insulin resistance, hepatic steatosis, non-alcoholic hepatic steatosis, fibrotic liver disease, vascular disease, and chronic intestinal inflammation.
Type:
Grant
Filed:
September 27, 2018
Date of Patent:
October 24, 2023
Assignees:
INmune Bio Inc, EMORY UNIVERSITY
Inventors:
Maria Elizabeth De Souza Rodrigues, Maria de Lourdes Gamez Tansey, Christopher J. Barnum, Raymond J. Tesi, Dean P. Jones, Douglas I. Walker